Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) EBITDA (2016 - 2025)

Jaguar Health (JAGX) has disclosed EBITDA for 11 consecutive years, with -$21.2 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 160.41% to -$21.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.9 million through Dec 2025, down 48.9% year-over-year, with the annual reading at -$45.9 million for FY2025, 48.9% down from the prior year.
  • EBITDA for Q4 2025 was -$21.2 million at Jaguar Health, down from -$7.2 million in the prior quarter.
  • The five-year high for EBITDA was -$6.3 million in Q4 2022, with the low at -$21.2 million in Q4 2025.
  • Average EBITDA over 5 years is -$9.3 million, with a median of -$8.5 million recorded in 2021.
  • The sharpest move saw EBITDA skyrocketed 44.05% in 2022, then tumbled 160.41% in 2025.
  • Over 5 years, EBITDA stood at -$10.8 million in 2021, then soared by 41.91% to -$6.3 million in 2022, then decreased by 20.22% to -$7.6 million in 2023, then decreased by 7.94% to -$8.2 million in 2024, then crashed by 160.41% to -$21.2 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$21.2 million, -$7.2 million, and -$8.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.